Loading organizations...
§ Private Profile · Emeryville, CA, USA
Tethys BioScience is a technology company.
Tethys BioScience develops biomarker-based blood tests predicting imminent disease risk, specifically in cardiometabolic diagnostics. Its core product identifies individuals at high risk for metabolic conditions like type 2 diabetes. Leveraging advanced biological markers, it provides early detection insights into disease progression, supporting proactive health management.
Dr. Mickey Urdea co-founded Tethys BioScience in 2002, utilizing his background from Bayer. His founding insight focused on transforming chronic disease management through earlier intervention. Urdea established the company to harness biomarker technology, aiming to shift healthcare from reactive treatment toward predictive prevention via novel diagnostics.
The company’s products equip physicians and patients with advanced tools for proactive health screening and risk assessment. Tethys BioScience’s vision was to reduce the burden of preventable chronic diseases. By delivering early diagnostic information, it aimed to empower timely interventions and improve patient outcomes through a preventative strategy.
Tethys BioScience has raised $58.0M across 2 funding rounds.
Tethys BioScience has raised $58.0M in total across 2 funding rounds.
Tethys BioScience has raised $58.0M across 2 funding rounds. Most recently, it raised $33.0M Debt / Series D in July 2010.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 21, 2010 | $33M Debt Financing | — | Greenspring Associates, Oxford Finance, Paul Capital, Silicon Valley Bank | Announced |
| Nov 1, 2009 | $25M Series D | George Rehm | Intel Capital, Kleiner Perkins, Mohr Davidow Ventures, Wasatch Funds | Announced |
Tethys BioScience has raised $58.0M in total across 2 funding rounds.
Tethys BioScience's investors include Greenspring Associates, Oxford Finance, Paul Capital, Silicon Valley Bank, George Rehm, Intel Capital, Kleiner Perkins, Mohr Davidow Ventures, Wasatch Funds.
Tethys Bioscience is a cardiometabolic diagnostics company that develops and commercializes biomarker-based blood tests to predict imminent risk of chronic diseases like type 2 diabetes, enabling targeted interventions.[1][3] Its flagship product, the PreDx® Diabetes Risk Score, launched in 2009 and has processed over 55,000 tests, with additional diagnostics in development for heart attack risk, osteoporotic fractures, and other cardiometabolic conditions.[1] The company, headquartered in Emeryville or West Sacramento, CA, raised $30.4 million across three funding rounds, including a $25 million round, and reported $27.8 million in revenue with around 131 employees before ceasing operations.[1][5]
Founded in 2002, Tethys Bioscience emerged to address gaps in metabolic disease diagnosis through biological markers, focusing on diabetes research and prevention.[3][5] The company quickly advanced its pipeline, initiating sales of the PreDx® Diabetes Risk Score in 2009—a pivotal moment that demonstrated early commercial traction with over 55,000 tests processed.[1] While specific founders are not detailed in available records, the firm's evolution centered on expanding from diabetes risk prediction to broader cardiometabolic biomarkers, supported by significant venture funding totaling $30.4 million.[1]
Tethys BioScience rode the early 2000s wave of personalized medicine and biomarker-driven diagnostics, a trend accelerating with advances in genomics and the rising global burden of cardiometabolic diseases like diabetes.[1][3] Timing was ideal post-Human Genome Project, when biomarker tech enabled precise risk prediction amid growing demand for preventive healthcare over reactive treatment. Market forces like aging populations and healthcare cost pressures favored its model, influencing the ecosystem by pioneering scalable blood tests that informed clinical decisions and spurred competitors in precision diagnostics.[1] Though now out of business, its PreDx® success contributed to validating biomarker tests in routine care.[5]
Tethys BioScience's legacy lies in proving biomarker diagnostics' viability for cardiometabolic risk prediction, but its out-of-business status since around 2015 signals challenges like market adoption hurdles or funding gaps in early biotech.[5] No active operations or recent news suggest no revival, though its IP or tech may live on via acquisitions. Trends like AI-enhanced biomarkers and wearables could reshape similar ventures, potentially amplifying Tethys-like innovations in preventive health—echoing its original mission to forestall chronic disease through early detection.[1]